| Project/Area Number |
23650620
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor diagnosis
|
|---|
| Research Institution | 公益財団法人東京都医学総合研究所 (2012)
Tokyo Metropolitan Organization for Medical Research (2011) |
|---|
Principal Investigator |
ENDO Fumiko 公益財団法人東京都医学総合研究所, ゲノム医科学研究分野, 研究員 (80546630)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIBASAKI Futoshi 公益財団法人東京都医学総合研究所, ゲノム医科学研究分野, 参事研究員 (90300954)
SAKURAI Akira 公益財団法人東京都医学総合研究所, ゲノム医科学研究分野, 研究員 (40546628)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KAWANA Kei 東京大学, 医学部附属病院, 講師 (60311627)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 子宮頸癌 / ワクチン / HPV / 子宮頸癌ワクチン / 中和抗体価 / 子宮頸癌予防ワクチン |
|---|
| Research Abstract |
Two kinds of human papillomavirus (HPV) vaccine currently commercialized in Japan are estimated that they would be able to protect approximately 70% of cervical cancer cases. On the other hand, the method of measurement on these HPV vaccine efficacies had not been established yet. In this study, we developed the original methods on measure the neutralized HPV types of 16 and 18 antibodies in sera, types which are known as the most typical high risk factors of cervical cancer, induced by the vaccination. We also practically evaluated pre-/post- vaccinated sera and found that the levels of antibody are certainly increased by HPV vaccine.
|
